Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

References

• WalshGMAntagonism of eosinophil accumulation in asthmaRecent Pat Inflamm Allergy Drug Discov20104321021320804449
   PubMedGoogle Scholar
• BousquetJChanezPLacosteJYEosinophilic inflammation in asthmaN Engl J Med199032315103310392215562
   PubMed Web of Science ®Google Scholar
• Nissim Ben EfraimAHLevi-SchafferFTissue remodeling and angiogenesis in asthma: the role of the eosinophilTher Adv Respir Dis20082316317119124368
   PubMedGoogle Scholar
• BlanchardCRothenbergMEBiology of the eosinophilAdv Immunol20091018112119231593
   PubMed Web of Science ®Google Scholar
• WalshGMAdvances in the immunobiology of eosinophils and their role in diseaseCrit Rev Clin Lab Sci199936545349610560888
   PubMed Web of Science ®Google Scholar
• EganRWUmlandSPCussFMChapmanRWBiology of interleukin-5 and its relevance to allergic diseaseAllergy199651271818738511
   PubMed Web of Science ®Google Scholar
• MolfinoNAGossageDKolbeckRParkerJMGebaGPMolecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptorClin Exp Allergy201242571273722092535
   PubMed Web of Science ®Google Scholar
• LongAAMonoclonal antibodies and other biologic agents in the treatment of asthmaMAbs20091323724620065638
   PubMed Web of Science ®Google Scholar
• WalshGMNovel cytokine-directed therapies for asthmaDiscov Med2011115928329121524382
   PubMed Web of Science ®Google Scholar
• CorrenJInhibition of interleukin-5 for the treatment of eosinophilic diseasesDiscov Med2012137130531222541618
   PubMed Web of Science ®Google Scholar
• LeckieMJten BrinkeAKhanJEffects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic responseLancet200035692482144214811191542
   PubMed Web of Science ®Google Scholar
• KipsJCO’ConnorBJLangleySJEffect of SCH55700, a humanized anti-human interleukin-5 antibody in severe persistent asthma: a pilot studyAm J Resp Crit Care Med2003167121655165912649124
   PubMed Web of Science ®Google Scholar
• Flood-PagePTMenzies-GowANKayABRobinsonDSEosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airwayAm J Respir Crit Care Med2003167219920412406833
   PubMed Web of Science ®Google Scholar
• Flood-PagePSwensonCFaifermanIfor International Mepolizumab Study GroupA study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaAm J Respir Crit Care Med2007176111062107117872493
   PubMed Web of Science ®Google Scholar
• O’ByrnePMThe demise of anti IL-5 for asthma, or notAm J Respir Crit Care Med2007176111059106018042659
   PubMed Web of Science ®Google Scholar
• RosenbergHFPhippsSFosterPSEosinophil trafficking in allergy and asthmaJ Allergy Clin Immunol200711961303131017481712
   PubMed Web of Science ®Google Scholar
• HaldarPBrightlingCEHargadonBMepolizumab and exacerbations of refractory eosinophilic asthmaN Engl J Med20093601097398419264686
   PubMed Web of Science ®Google Scholar
• NairPPizzichiniMMKjarsgaardMMepolizumab for prednisone-dependent asthma with sputum eosinophiliaN Engl J Med20093601098599319264687
   PubMed Web of Science ®Google Scholar
• CookWJWalterLJMurgoloNJStructure and humanization of a rat monoclonal Fab to human interleukin-5Protein Eng1995976236288844835
   PubMedGoogle Scholar
• EganRWAthwalDBodmerMWEffect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivityArzneimittelforschung199949977979010514907
   PubMed Web of Science ®Google Scholar
• WalshGMReslizumab, a humanized monoclonal anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditionsCurr Opin Mol Ther200911332933619479666
   PubMedGoogle Scholar
• EganRWAthwahlDChouCCInhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5Int Arch Allergy Immunol19951071–33213227613159
   PubMed Web of Science ®Google Scholar
• BatemanNDShahiAFeeleyKMWoolfordTJActivated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patientsClin Otolaryngol200530322122516111416
   PubMed Web of Science ®Google Scholar
• CastroMMathurSHargreaveFfor Res-5-0010 Study GroupReslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled studyAm J Respir Crit Care Med2011184101125113221852542
   PubMed Web of Science ®Google Scholar
• WechslerMEFulkersonPCBochnerBSNovel targeted therapies for eosinophilic disordersJ Allergy Clin Immunol2012130356357122935585
   PubMed Web of Science ®Google Scholar
• LiacourasCAFurutaGTHiranoIEosinophilic esophagitis: updated consensus recommendations for children and adultsJ Allergy Clin Immunol2011128132021477849
   PubMed Web of Science ®Google Scholar
• De AngelisPMorinoGPaneAEosinophilic esophagitis: management and pharmacotherapyExpert Opin Pharmacother20089573174018345951
   PubMed Web of Science ®Google Scholar
• BlanchardCRothenbergMEBasic pathogenesis of eosinophilic esophagitisGastrointest Endosc Clin N Am2008181133143x18061107
   PubMedGoogle Scholar
• BlanchardCStuckeEMRodriguez-JimenezBA striking local esophageal cytokine expression profile in eosinophilic esophagitisJ Allergy Clin Immunol2011127120821721211656
   PubMed Web of Science ®Google Scholar
• SpergelJMRothenbergMECollinsMHReslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trialJ Allergy Clin Immunol20121292456463e1322206777
   PubMed Web of Science ®Google Scholar
• BlanchardCWangNStringerKFEotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitisJ Clin Invest2006116253654716453027
   PubMed Web of Science ®Google Scholar
• LiuLYSedgwickJBBatesMEDecreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated processJ Immunol2002169116459646612444155
   PubMed Web of Science ®Google Scholar
• LiuLYSedgwickJBBatesMEDecreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challengeJ Immunol2002169116452645812444154
   PubMed Web of Science ®Google Scholar
• GevaertPBachertCHoltappelsGEnhanced soluble interleukin-5 receptor alpha expression in nasal polyposisAllergy200358537137912752323
   PubMed Web of Science ®Google Scholar
• GevaertPLang-LoidoltDLacknerANasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polypsJ Allergy Clin Immunol200611851133114117088140
   PubMed Web of Science ®Google Scholar
• KlionADLawMANoelPKimYJHavertyTPNutmanTBSafety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndromeBlood200410382939294115070668
   PubMed Web of Science ®Google Scholar